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Objectives
Commonly used measures of engagement in HIV care do not take into account that the frequency
of attendance is related to changes in treatment and health status. This study developed a new
measure of engagement in care (EIC) incorporating clinical factors.
Methods
We conducted semi-structured interviews with eight HIV physicians to identify factors associated with
the timing of patients’ next scheduled appointments. These factors informed the development of an
algorithm to classify each month of follow-up as “in care” (on or before the time of the next expected
attendance) or “out of care” (after the time of the next expected attendance). The EIC algorithm was
applied to data from the UK Collaborative HIV Cohort (UK CHIC) study, a large clinical cohort study.
Results
The interviews indicated that time to next appointment varied depending on psychosocial and
physical comorbidities, and clinical factors (time since diagnosis, AIDS diagnosis, treatment status,
CD4 count and viral load). The resulting EIC algorithm was applied to 44 432 patients; 83.9% of
the 3 021 224 person-months were “in care”. Greater EIC was independently associated with older
age, white ethnicity, HIV acquisition through sex between men, current use of antiretroviral
therapy (ART), a higher nadir CD4 count, later calendar year and being seen at the clinic for the
first time within the last year.
Conclusions
This algorithm describing engagement in HIV care incorporates a time-updated measure of
patients’ treatment and health status. It adds to the options available for measuring this key
performance indicator.
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Introduction
The introduction of combination antiretroviral therapy
(ART) has led to a dramatic reduction in HIV-associated
morbidity and mortality [1]. While the life expectancy for
successfully treated people living with HIV in the UK is
now similar to that of the general population [2], patients
who do not attend all their HIV clinic appointments
remain at higher risk of long-term mortality [3]. ART is
also recognized as an effective means of reducing HIV
transmission [4] and yet the individual and public health
benefits of HIV treatment can only be achieved if people
living with HIV are aware that they are HIV positive and
have sustained engagement with care.
Engagement in out-patient HIV care is therefore a key
measure of quality performance for HIV service providers
[5] and a number of measures have been proposed. The
Correspondence: Dr Alison R. Howarth, UCL Centre for Sexual Health &
HIV Research, Mortimer Market Centre, off Capper Street, London WC1E
6JB, UK. Tel: +44 20 3108 2070; fax: +44 20 3108 2079; e-mail: alison.
howarth@ucl.ac.uk
aSee Appendix a.
bSee Appendix b.
This is an open access article under the terms of the Creative Commons
Attribution License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited.
1
DOI: 10.1111/hiv.12427
© 2016 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. HIV Medicine (2016)
ORIGINAL RESEARCH
number or proportion of missed appointments has been
used where these data are available [3,6]. In the absence
of appointment data, measures often rely on laboratory
data as surrogate markers of attendance. This can be used
to measure visit constancy [6], which assesses the propor-
tion of time intervals in which patients attend for care on
at least one occasion: a recent Danish study, for example,
used the proportion of person-years where patients had at
least one contact with the HIV care system [7]. Another
study defined suboptimal care as years when fewer than
two CD4 count or viral load measurements occurred per
calendar year [8]. The Health Resources and Services
Administration HIV/AIDS Bureau (HRSA HAB) measure
has been used to examine the proportion of years where
patients have at least two out-patient visits separated by
90 days [9,10]. A comparison of a measure based on gaps
between visits of more than 6 months with a 91-day mea-
sure of constancy and the HRSA HAB measure found
moderately strong correlation between measures [11].
There is no gold standard measure of engagement in
HIV out-patient care. While each of the above measures
has its own strengths and weaknesses [6], none of them
takes into account that the frequency of attendance is
related to changes in treatment and health status and
may also be affected by external forces or changes in
clinic policy. In the UK, for example, British HIV Associa-
tion (BHIVA) guidelines indicate that patients should be
seen within 2–4 weeks of starting ART and every
3–6 months for routine monitoring on ART if they are
considered “stable” and have good adherence and an
undetectable viral load [12]. More recently, however,
clinics have switched to a policy of less frequent moni-
toring in this subgroup in accordance with best practice
and in order to manage an increasing clinic load in the
setting of reduced resources for HIV health care. A recent
study suggests that annual CD4 monitoring may be
appropriate for virally supressed patients with a baseline
CD4 count of ≥ 250 cells/lL [13].
The Retention and Engagement Across Care Services
for HIV (REACH) study set out to better understand HIV
out-patient attendance in order to develop cost-effective
interventions to optimize engagement in care (EIC). Tak-
ing into account that the frequency of monitoring is
dependent on treatment and health status, and as gaps
between clinic visits may vary quite considerably within
the current guidelines [12], we conducted interviews with
physicians about the factors that influence the timing of
a patient’s next scheduled appointment. The information
was used to inform the development of an algorithm that
can be used to provide a measure of EIC that is sensitive
to changes in an individual’s status over time. The aim of
this present study was to describe the initial development
of this algorithm and its application to a large clinical
cohort in the UK.
Methods
Algorithm development
Exploratory, semi-structured, face-to-face interviews were
conducted with eight HIV physicians with a range of
clinical experience selected from five HIV out-patient
clinics in inner and outer London where the prevalence
of HIV is high [14]. The physicians were purposively
selected to ensure representation from each of the five
clinics which had previously agreed to participate in the
REACH study. They were of various sizes and covered
different patient populations in north, east and central
London. All clinics were based in specialist services for
sexual health and HIV and attended by general HIV
out-patients.
The interviews, which were conducted by AH, took 25–
30 min and were recorded verbatim. Physicians were
asked to describe the factors that prompted the timing of
the next scheduled appointment for the last ten patients
that they had seen: specifically, they were asked when
they had asked to see the patient again (number of
weeks/months) and why. Interviews took place from
November 2013 to February 2014 and the findings there-
fore reflect guidelines in place at the time [12]. Physi-
cians were asked not to provide any information that
would identify patients.
We conducted a content analysis [15] of these qualita-
tive data. For each patient, we noted the time to the next
scheduled appointment and the key reason for the timing
of this appointment given by their physician. We then
identified factors under which to code the key reasons. The
data were entered into SPSS STATISTICS 22 (IBM Corporation,
Armonk, New York, USA) to produce a cross-tabulation of
time to appointment by factor. The findings from this anal-
ysis informed the development of an algorithm to measure
EIC that was refined iteratively to the precision required
for programming.
Application of the algorithm to a clinical data set
The algorithm was applied to data from the UK Collabo-
rative HIV Cohort (UK CHIC) study and analyses were
performed using SAS 9.3 (SAS Institute, Cary, NC). UK
CHIC collates routine data on HIV-positive people, aged
16 years or older, who have attended some of the largest
HIV clinics in the UK since 1 January 1996. For this
analysis, we included all patients who attended a partici-
pating UK CHIC clinic on two or more occasions between
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1 January 2000 and 31 December 2012. In the absence of
complete data on clinic attendances, CD4 counts, viral
loads, haemoglobin measurements and ART start or
switch dates were used as markers of clinic attendance.
Follow-up for each person was considered to continue
until the last recorded laboratory marker or clinic visit
prior to (or on) 31 December 2012.
Individuals may often have repeat laboratory tests per-
formed within a short time interval to confirm unex-
pected findings, and this may result in clusters of
measurements around a single “index” date. For our
analysis, we did not want to consider each of the mea-
surements within a cluster as independent visits, as only
the index visit would have been scheduled at the previ-
ous visit. Thus, we grouped attendances into “care epi-
sodes”, defined as months (period of 30.4 days since
entry into the study) where at least one visit occurred.
For each care episode, we then established the lowest
CD4 count measured in that month (and the change from
the previous value), the highest HIV viral load (and the
status of this measurement relative to other consecutive
values) and the patient’s treatment status, and used this
information to establish a likely date of next scheduled
visit using our algorithm (see Results and Fig. 1 for an
example of the application of the algorithm). The date of
the next observed care episode determined whether the
patient had attended before or after the expected date,
and each patient-month was then classified as being
in care (where it occurred on or before the time of the
next expected care episode) or out of care (where it
occurred after the time of the next expected care episode)
accordingly.
Statistical methods
The proportion of months where patients were engaged
in HIV care was calculated overall and for patient
subgroups defined by gender, age group (< 25, 25–45 and
> 45 years), ethnic group (white, black African, other
and unknown), mode of HIV acquisition (sex between
men, sex between men and women, injecting drug use
and other/unknown), whether currently on ART, nadir
and current CD4 counts (both classified as < 200, 200–
349 and ≥ 350 cells/lL), participating clinic, calendar
year (2000–2003, 2004–2007 and 2008–2012) and time
since entry in the study (< 1, 1–5, 5–10 and > 10 years).
Note that we did not consider follow-up after the
patient’s last reported care date, and therefore this
algorithm focuses on intermittent periods of disengage-
ment rather than ultimate loss to follow-up after the
person’s last clinic visit. Each patient-month was then
treated as a separate entry in a multivariable logistic
regression model with the aim of identifying demo-
graphic and clinical factors associated with that month
being “in care”. These models were fitted using PROC
GENMOD in SAS, with generalized estimating equations
being used to take account of the repeated entries within
each individual patient.
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Fig. 1 Measure of engagement in HIV care applied to an individual case. In this example, the patient was diagnosed with a CD4 count of
420 cells/lL and a viral load of 4.0 log10 copies/mL. As she was diagnosed during this care episode, we expect to see her again within
2 months (E). However, she did not re-attend until 4 months after diagnosis (O). Thus, months 1 and 2 are defined as being in care (light
shading) and months 3 and 4 as being out of care (dark shading). By the time of her next care episode, her CD4 count had fallen to
370 cells/lL so we expect to see her again within 4 months but she actually re-attended after 5 months; thus, months 5–8 are in care and
month 9 is out of care. At the next care episode, she started antiretroviral therapy (ART) so we expect to see her again within 2 months. As
she did not re-attend until 3 months later, months 10 and 11 are defined as in care and month 12 is out of care. She then re-attended after
1 month, by which time her CD4 count was back up to 420 cells/lL and her viral load was undetectable - which means that we would not
expect to see her for another 6 months (with follow-up ending at 5 months in this example).
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Results
Qualitative interviews with physicians
A total of 73 patients were discussed in the physician
interviews. One patient was not included in the analysis
because their next appointment was dependent on
awaited test results. The time of the next scheduled
appointment was missing for another patient and not
available for a further five patients who had not attended
their last scheduled appointment at the time of the physi-
cian interviews.
The time of the next scheduled appointment in the
remaining 66 patients ranged from 1 week to 6 months,
with a median of 3 months. While physicians were acting
within the current guidelines, they described the reasons
for this variation in the timing of the next scheduled
appointment. Five factors were identified from the con-
tent analysis of the interview data as instrumental. These
factors were summarized as “routine” where patients were
stable and required routine follow-up, “virological” where
the next appointment was based on change in viral load
(uncontrolled or virological breakthrough), “treatment”
where the next appointment was related to starting ART
or changing an existing ART regimen, “psychosocial”
where mental health or psychosocial issues were identi-
fied as instrumental, and “physical comorbidities” where
a range of physical comorbidities were given as the key
reason for the timing of the next appointment.
One-third of patients were described as stable and given
routine follow-up appointments 4–6 months after their
last visit. Routine follow-up for one pregnant woman was
arranged for 3 months’ time. Physicians talked about
extending routine visits to every 6 months when patients
were well and stable, both on treatment and in their psy-
chosocial circumstances. Changes in viral load brought the
next scheduled appointment forward to 1–2 months after
the last. Patients who were starting or changing treatment
were given a next appointment date between 2 and
12 weeks later, depending on the treatment start date and
virological response or when treatment was planned to
start. Follow-up appointments of between 1 week and
4 months later were arranged depending on a range of
psychosocial issues (from specific concerns about mental
health to more general needs for social support) and
comorbidities: both of which required earlier follow-up
when patients were often otherwise stable on treatment.
Algorithm development
We used the data from the physician interviews on the
timing of next appointments as the basis for developing
the EIC algorithm. Although psychosocial wellbeing and
comorbidities were key factors in determining the expected
time between patient visits to the HIV clinic, data on these
variables are not generally captured electronically and are
not often available in routinely collected cohort data.
Thus, we used clinical data (HIV diagnosis, AIDS diagnosis,
treatment start dates, CD4 count and viral load) only to
determine the patient’s treatment and health status. This
was used to estimate the expected time to the next sched-
uled care episode, in accordance with the data collected in
the physician interviews (Table 1). The EIC algorithm was
then refined for programming.
According to the EIC algorithm, the shortest expected
gap between care episodes was 2 months. This is to
allow for the fact that clinic visits might occur at any
point during the month or care episode into which they
are grouped. If the patient was within 1 month of diag-
nosis, had an AIDS diagnosis, or started ART or changed
ART at the initial care episode, the next care episode
Table 1 Conditions associated with the expected time of the next
scheduled care episode
Conditions at time of initial care episode*
Next care episode
expected within
Within 1 month of HIV diagnosis 2 months
AIDS diagnosis 2 months
Started ART 2 months
Started new combination 2 months
Not on ART
CD4 count ≤ 350 cells/lL
any drop in CD4 count
2 months
CD4 count ≤ 350 cells/lL;
no drop in CD4 count
4 months
CD4 count 351–499 cells/lL 4 months
CD4 count ≥ 500 cells/lL;
CD4 count drop ≥ 100 cells/lL
4 months
CD4 count ≥ 500 cells/lL;
CD4 count drop < 100 cells/lL;
viral load ≥ 100 000 copies/mL
4 months
CD4 count ≥ 500 cells/lL;
CD4 count drop < 100 cells/lL;
viral load < 100 000 copies/mL
6 months
Already started ART
Viral load > 200 copies/mL 2 months
Viral load 51–200 copies/mL;
does not appear to be blip†
2 months
Viral load 51–200 copies/mL;
appears to be blip
4 months
Viral load ≤ 50 copies/mL;
CD4 count ≤ 200 cells/lL
4 months
Viral load ≤ 50 copies/mL
CD4 count > 200 cells/lL
6 months
ART, antiretroviral therapy.
*If more than one condition applies at the time of the care episode, the
next care episode is expected within the least number of months associ-
ated with those conditions.
†
Blips are defined as having a viral load of between 50 and 200 HIV-1
RNA copies/mL following a previous viral load of < 50 copies/mL.
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was expected within 2 months. If the patient was not
on ART at the initial care episode, the next care episode
was expected within 2–6 months, depending mainly on
CD4 count. If the patient had started ART, it was
expected within 2–6 months, depending on viral load.
We used 6 months as the maximum time between visits,
as described in the physician interviews. If more than
one condition applied at the time of the initial care epi-
sode, the next care episode was expected within the
least number of months associated with those condi-
tions.
Fig. 1 shows an example of how the EIC algorithm is
applied to an individual case. In this example, the
patient was out of care for 4 of her 18 months of fol-
low-up and was therefore in care for 14/18 = 77.8% of
months.
Associations between engagement in care and factors
identified in UK CHIC
A total of 44 432 patients from UK CHIC (2000–2012)
were included in the following analysis. Women
represented 27.8% of the sample. Half were white
(53.3%), one-third were black African (28.9%), 8.7% were
of other ethnicity and 9.2% had unknown ethnicity.
Around half had acquired HIV through sex between men
(50.5%), with 39.1% acquiring HIV through sex between
men and women, 3.0% through injecting drug use and
the remaining 7.4% through other or unknown routes.
Their median age at entry into the study was 36 years
[interquartile range (IQR) 30–42 years] and the median
date of follow-up start was December 2004 (range Jan-
uary 2000 to October 2012). The median CD4 count at
start of follow-up was 355 (IQR 214–520) cells/lL;
patients were followed for a median of 61 (range 2–156)
months with a total follow-up of 3 021 224 patient-
months.
Overall, patients were engaged in care for 83.9% of the
total follow-up of patient-months. Table 2 shows the pro-
portion of months that were engaged in care stratified by
the various demographic and clinical factors, as well as
the results of univariable and multivariable regression
models. In univariable analyses, EIC was higher in men,
in those aged > 45 years, in those of white ethnicity, in
Table 2 Unadjusted and adjusted associations with retention in care in any particular month
Factor
Unadjusted Adjusted*
Person-months % retention in care OR (95% CI) P-value OR (95% CI) P-value
Gender Male 2 235 135 85.1 1.36 (1.31, 1.40) 0.0001 1.10 (0.98, 1.23) 0.11
Female 786 089 80.7 1 – – 1 – –
Age group < 25 years 83 116 77.1 0.63 (0.42, 0.93) 0.02 0.67 (0.42, 1.06) 0.09
25–45 years 1 960 061 82.5 0.66 (0.53, 0.81) 0.0001 0.74 (0.59, 0.93) 0.008
> 45 years 978 023 87.4 1 – – 1 – –
Ethnic group White 1 760 442 85.5 1 – – 1 – –
Black African 802 477 81.2 0.74 (0.71, 0.76) 0.0001 0.96 (0.83, 1.11) 0.55
Other 239 190 81.8 0.77 (0.73, 0.81) 0.0001 0.79 (0.68, 0.92) 0.002
Unknown 219 115 83.6 0.87 (0.82, 0.92) 0.0001 0.87 (0.73, 1.03) 0.11
Route of acquisition MSM 1 687 095 86.2 1 – – 1 – –
IDU 94 014 76.3 0.52 (0.48, 0.56) 0.0001 0.56 (0.44, 0.71) 0.0001
Heterosexual 1 127 473 81.4 0.70 (0.68, 0.73) 0.0001 0.84 (0.73, 0.98) 0.02
Other/unknown 112 642 82.2 0.77 (0.71, 0.83) 0.0001 0.80 (0.67, 0.95) 0.01
Currently on ART No 616 201 74.6 1 – – 1 – –
Yes 2 405 023 86.3 0.95 (0.79, 1.15) 0.62 1.44 (1.15, 1.81) 0.002
Nadir CD4 count < 200 cells/lL 1 528 352 87.8 0.51 (0.40, 0.65) 0.0001 0.55 (0.41, 0.74) 0.0001
200–349 cells/lL 821 951 84.3 0.33 (0.25, 0.45) 0.0001 0.37 (0.28, 0.50) 0.0001
≥ 350 cells/lL 571 445 76.7 1 – – 1 – –
Current CD4 count < 200 cells/lL 256 512 80.8 0.68 (0.53, 0.87) 0.002 0.82 (0.64, 1.05) 0.12
200–349 cells/lL 587 648 82.7 0.81 (0.69, 0.94) 0.006 0.93 (0.81, 1.08) 0.34
≥ 350 cells/lL 2 077 588 85.7 1 – – 1 – –
Calendar year 2000–2003 553 178 82.5 0.59 (0.50, 0.70) 0.0001 0.61 (0.51, 0.72) 0.0001
2004–2007 1 500 392 85.2 1 – – 1 – –
2008–2012 967 654 82.8 1.68 (1.45, 1.94) 0.0001 1.71 (1.47, 1.98) 0.0001
Time since < 1 year 351 190 87.4 1.80 (1.34, 2.40) 0.0001 1.53 (1.09, 2.15) 0.01
Entry in UK 1–5 years 1 137 979 82.5 1.19 (0.89, 1.59) 0.24 1.24 (0.89, 1.71) 0.20
CHIC 5–10 years 1 020 656 83.4 1.22 (0.92, 1.61) 0.16 1.13 (0.85, 1.51) 0.41
> 10 years 511 399 85.8 1 – – 1 – –
ART, antiretroviral therapy; CI, confidence interval; IDU, injecting drug use; MSM, men who have sex with men; OR, odds ratio; UK CHIC, UK Collabora-
tive HIV Cohort.
*Adjusted for other variables shown in the table and for clinic.
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those who acquired HIV through sex between men, in
those with higher nadir and current CD4 counts, in later
calendar years and in those who had only recently
(within the last year) been first seen at the clinic. After
adjustment for other factors shown in Table 2 and for
clinic, most of these associations were unchanged with
three main exceptions. Firstly, there was no strong asso-
ciation between gender and EIC. Secondly, while current
use of ART did not appear to be associated with EIC in
unadjusted analyses, after adjustment it became apparent
that those currently on ART had higher levels of engage-
ment. Finally, including adjustment for the nadir CD4
count showed that current CD4 count did not provide
any independent association with EIC.
Discussion
We have developed an algorithm which provides a flexi-
ble new approach to measuring engagement in out-
patient HIV care. It is, to our knowledge, the first mea-
sure that adapts to the changing treatment and health
status of the patient, reflecting the reality described to us
by physicians and giving it strong face validity [6]. The
EIC algorithm can also be easily modified at a clinic level
and/or over time to reflect changes in service delivery or
treatment criteria, or when comparing EIC across different
sites with different monitoring frequencies.
The algorithm provides a dichotomous measure for
each month of follow-up as to whether the patient is in
care or out of care. Poor EIC during the first year after
diagnosis is associated with a higher rate of mortality [3]
and the algorithm may be usefully applied to this period,
as shown in our illustrative example, in addition to other
key short periods of time, such as the first year after giv-
ing birth. It can be used in longitudinal analysis of pat-
terns of engagement over extended periods of time [16]
and to examine associations between predictive variables
and the proportion of months that patients are in care
following diagnosis.
We found that patients were engaged in care for
83.9% of months over a follow-up period of up to
12 years. Consistent with findings from an analysis of
loss to follow-up in the annual Survey of Prevalent HIV
Infections Diagnosed in England, Wales and Northern
Ireland [17], greater engagement in HIV care was more
likely in men who have sex with men, and those who
were less engaged were more likely to be women, of
black ethnicity and younger. Studies using a range of
measures of retention and engagement have also found
that HIV patients are less likely to disengage from care
if they are older [18–20], white [21], men who have sex
with men [21,22], and have started ART [17,18]. The
consistency in these findings provides a measure of
external validity for the algorithm.
The EIC algorithm was developed from interviews with
physicians who indicated that the timing between
appointments is dependent on a range of factors. The
interviews clearly illustrate that there is no one-size-fits-
all when it comes to the timing of HIV clinic appoint-
ments. Patients stable on treatment were seen for routine
care every 4 months which was extended to every
6 months, as appropriate for the individual under care,
guided by the therapeutic relationship. We have used
6 months as the maximum time between routine visits in
the algorithm, as described by physicians in accordance
with the UK guidelines for routine monitoring [12]. How-
ever, the EIC algorithm could be adapted to changing
guidelines for monitoring HIV patients and to local clinic
policies on how often to see patients. For example, new
treatment guidelines in the UK recommend starting ART
irrespective of CD4 count [23] and this should be incor-
porated into the EIC algorithm when it is applied to
future cohort data.
The majority (90%) of people who are being seen for
HIV care in the UK are on ART [14]. This was also the
case among patients discussed in our physician interviews
and the data they provided on response to treatment and
virological breakthrough informed the development of
the EIC algorithm. Psychosocial issues and comorbidities
also played a key role in the timing of patients’ next
scheduled appointments – although this finding may be
limited by an over-representation of more complex
patients in our study, reflecting the clinical interests and
patient cohorts of the physicians who took part in our
interviews. Patients affected by these factors were sched-
uled to come back within a shorter period of time, from
1 week to 4 months. While such data are not currently
collected for UK CHIC, they could be incorporated into an
algorithm if they were available. For example, the new
UK HIV and AIDS Reporting System (HARS) [24] includes
a measure of patient complexity that could be incorpo-
rated into future iterations of the EIC algorithm. The EIC
algorithm may therefore provide an under-estimation of
engagement in HIV care as it does not account for
patients whom physicians may wish to see earlier for
treatment of comorbidities and psychosocial issues asso-
ciated with HIV.
In common with other analyses of EIC using HIV
cohort data, we have used laboratory data and ART start
dates as surrogate markers of clinic visits. It is possible,
therefore, that we may have missed some visits where no
laboratory test was performed. Further analyses of data
from the group of clinics that are able to provide more
detailed information on attendances will allow us to
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validate this approach. We grouped visits into care epi-
sodes to negate the effect of repeated laboratory measure-
ments within short time intervals.
We censored the data at the last recorded visit and,
while our measure does not therefore include any ongo-
ing periods of loss to follow-up, it would be possible to
incorporate this into the algorithm. It should also be
noted that any algorithm is clearly only an approxima-
tion to a far more complex clinical process and it is dif-
ficult in an observational cohort setting to incorporate
other factors, such as social factors, that may lead to
more regular scheduled visits. This is, however, likely to
result in an under-estimation of EIC rather than an
over-estimation. While our algorithm has these limita-
tions, we have created a measure of engagement in HIV
care that will benefit from the advantages of using these
data [25], with the associated years of follow-up, statis-
tical power and representative patient populations. The
EIC algorithm can be used to examine how patients
engage in HIV care over time and identify variables
associated with disengagement, with the aim of achiev-
ing the best possible health outcomes for all [1]. In
future work, we will consider the associations between
EIC and longer term outcomes among individuals receiv-
ing ART.
EIC is a key quality performance measure for HIV ser-
vice providers and it is important that it is captured in a
way that reflects whether patients are attending as fre-
quently as indicated by their clinical needs. We have pre-
sented a concept of how to measure engagement in HIV
care by incorporating a time-updated measure of patients’
treatment and health status and a prototype of this mea-
sure that we have tested on HIV cohort data. The EIC
algorithm adds to the options available for measuring
engagement in HIV care, and assessing this key perfor-
mance indicator.
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London NHS Foundation Trust (F. Burns).
Appendix b: The UK CHIC study
UK CHIC Steering Committee: Jonathan Ainsworth, Sris
Allan, Jane Anderson, Abdel Babiker, David Chadwick,
Valerie Delpech, David Dunn, Martin Fisher, Brian Gaz-
zard, Richard Gilson, Mark Gompels, Phillip Hay, Teresa
Hill, Margaret Johnson, Sophie Jose, Stephen Kegg, Clif-
ford Leen, Fabiola Martin, Mark Nelson, Chloe Orkin,
Adrian Palfreeman, Andrew Phillips, Deenan Pillay, Frank
Post, Jillian Pritchard, Caroline Sabin, Memory Sachiko-
nye, Achim Schwenk, Anjum Tariq, Roy Trevelion and
John Walsh.
UK CHIC Central Co-ordination: University College
London (Teresa Hill, Sophie Jose, Andrew Phillips, Caro-
line Sabin, Alicia Thornton and Susie Huntington); Medi-
cal Research Council Clinical Trials Unit at UCL (MRC
CTU at UCL), London (David Dunn and Adam Glabay).
UK CHIC Participating Centres: Brighton and Sussex
University Hospitals NHS Trust (M. Fisher, N. Perry, S.
Tilbury, E. Youssef and D. Churchill); Chelsea and West-
minster Hospital NHS Foundation Trust, London (B. Gaz-
zard, M. Nelson, R. Everett, D. Asboe and S. Mandalia);
King’s College Hospital NHS Foundation Trust, London
(F. Post, H. Korat, C. Taylor, Z. Gleisner, F. Ibrahim and L.
Campbell); Mortimer Market Centre, University College
London (R. Gilson, N. Brima and I. Williams); Royal Free
NHS Foundation Trust/University College London (M.
Johnson, M. Youle, F. Lampe, C. Smith, R. Tsintas, C.
Chaloner, S. Hutchinson, C. Sabin, A. Phillips, T. Hill, S.
Jose, A. Thornton and S. Huntington); Imperial College
Healthcare NHS Trust, London (J. Walsh, N. Mackie, A.
Winston, J. Weber, F. Ramzan and M. Carder); Barts and
The London NHS Trust, London (C. Orkin, J. Lynch, J.
Hand and C. de Souza); Homerton University Hospital
NHS Trust, London (J. Anderson and S. Munshi); North
Middlesex University Hospital NHS Trust, London (J.
Ainsworth, A. Schwenk, S. Miller and C. Wood); The
Lothian University Hospitals NHS Trust, Edinburgh (C.
Leen, A. Wilson and S. Morris); North Bristol NHS Trust
(M. Gompels and S. Allan); Leicester, University Hospitals
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of Leicester NHS Trust (A. Palfreeman, K. Memon and
A. Lewszuk); Middlesbrough, South Tees Hospitals NHS
Foundation Trust (D. Chadwick, E. Cope and J. Gibson);
Woolwich, Lewisham and Greenwich NHS Trust (S.
Kegg, P. Main, S. Mitchell and M. Hunter), St George’s
Healthcare NHS Trust (P. Hay and M. Dhillon); York
Teaching Hospital NHS Foundation Trust (F. Martin and
S. Russell-Sharpe); Coventry, University Hospitals
Coventry and Warwickshire NHS Trust (S. Allan, A.
Harte and S. Clay); Wolverhampton, The Royal Wolver-
hampton Hospitals NHS Trust (A. Tariq, H. Spencer and
R. Jones); Chertsey, Ashford and St Peter’s Hospitals
NHS Foundation Trust (J. Pritchard, S. Cumming and C.
Atkinson); Public Health England, London (V. Delpech);
UK Community Advisory Board (M. Sachikonye and R.
Trevelion).
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